熱門資訊> 正文

InflaRx股价突破1美元后重新合规

2026-04-28 19:53

InflaRx N.V. on Tuesday said it had regained compliance with Nasdaq’s minimum bid price requirement, after its shares closed at or above $1.00 for 10 consecutive business days between April 13 and April 24.
The company received written confirmation from Nasdaq on April 27 that the matter has been resolved and is now closed.
InflaRx develops anti-inflammatory therapies targeting the complement system, with lead programs including izicopan and vilobelimab currently in clinical development.

More on InflaRx

InflaRx N.V. (IFRX) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Slideshow
InflaRx receives Nasdaq notification
Seeking Alpha’s Quant Rating on InflaRx
Historical earnings data for InflaRx
Financial information for InflaRx

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。